# Fred Hutch/UWMC Kidney Cancer Studies

## TELIX Zircon Study
- **PET/CT imaging of ccRCC with IRM**
- **NCT03849118**
- PI: Chen / Coordinator: Tsang

## Merck MK6482-022
- Belzutifan (MK-6482) + Pembro (MK-3475) vs Placebo + Pembro, in the Adjuvant Treatment of (ccRCC) Post Nephrectomy
- **NCT05239728**
- PI: Tykodi | Coordinator: Jacobs

## iPREDICT Trial
- PET/CT study for Patients with Metastatic malignancies receiving Immunotherapy
- **RG1121794**
- PI: Chen | Coordinator: Tsang

## Merck MK6482-011
- Belzutifan + Lenvatinib vs Cabozantinib for pts who have progressed after prior PD-1/PDL-1 therapy
- **NCT04586231**
- PI: Tykodi | Coordinator: Jacobs

## NiKang NKT2152 101
- Phase 1 study of HIF-2-alpha inhibitor in patients with advanced clear cell renal cell carcinoma
- **RG1122075**
- **NCT05119335**

---

**KEY:**
- **Open:** Green/Bold
- **Not Yet Open:** Blue/Italicized
- **Non-therapeutic:** Gray background

For more information, search the NCT# at [clinicaltrials.gov](https://clinicaltrials.gov) or refer a patient by calling (206) 606-1062.